InforMedix CEO Named Chairman of the Board of the Institute on Aging at the University of Pennsylvania
InforMedix Holdings, Inc. (OTCBB: IFMX) announced today that its CEO, Bruce A. Kehr, M.D., was named Chairman of the External Advisory Board of the Institute on Aging (IOA) at the University of Pennsylvania. Penn’s IOA and faculty researchers are nationally renowned for their work in Alzheimer’s disease, Parkinson’s disease and other late-life chronic diseases. The IOA’s External Advisory Board is comprised of leaders in the fields of aging, national health policy in aging research including White House and Congressional relationships, Alzheimer’s disease, senior living and assisted living, public affairs, and media coverage of aging-related issues.
“We are excited to have Dr. Kehr Chair our Board,” said John Q. Trojanowski, M.D., Ph.D. Director of the Institute on Aging at the University of Pennsylvania. “Bruce is already assisting us in recruiting to the Board innovative national experts in chronic care disease management services to the aged, and will make an important contribution to our research and education programs regarding medication non-adherence in senior citizens. He will assist us in achieving the mission of the Institute on Aging, which is to improve the health of the elderly by increasing the quality and quantity of clinical and basic research, as well as educational programs focusing on normal aging and aging related disease.”
Dr. Bruce Kehr, chairman and CEO of InforMedix remarked, “I am honored that the University of Pennsylvania has appointed me Chairman of its Board of the Institute on Aging. This is a great opportunity to further the understanding of medication non-adherence in senior citizens, and promote research endeavours using telehealth technologies combined with disease management programs to enable seniors to “age gracefully in place.” I am excited to participate with renowned Board members including pioneering business leaders in aging services.”
As of November 2005, the members of IOA’s External Advisory Board are: Richard P. Brown, Jr. Esquire, Counsel, Morgan Lewis & Bockius, LLP; Willo Carey, Executive Director, Wider Horizons, WHYY, Inc.; Christine Cassel, M.D., President and CEO, American Board of Internal Medicine; James E. Eden, Chairman and President, Eden & Associates; Robert Kasirer, Chairman and CEO, HealthCare Continuum; Barbara Kleger, President, KD Partners, LLC; C. Raymond Larkin, Jr., General Partner, 3X Nell, LLC; James L. McCabe, Ph.D., President, McCabe Capital Managers Ltd.; Daniel (Dan) Perry, Executive Director, Alliance on Aging Research; Vivian W. Piasecki; Orien Reid, Former Chair, National Board of Directors, Alzheimer’s Disease Association; Thomas S. Rittenhouse, Managing Director, Ralston House; Gerald (Barry) B. Rorer, Senior Vice President, Rorer Group Inc.; Don Weissman, M.D., Vice President, Strategic Accounts, Medsn Inc.; and Linton A. Whitaker, M.D., Chief, Division of Plastic Surgery, PENN Medicine.
About InforMedix
InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients’ medication and care plan adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and care plan adherence in disease management and clinical drug trials programs. The Med-eMonitor System leverages InforMedix’s strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix’s patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB: IFMX), visit our website at www.informedix.com.
This report contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. References made to the discussion of the risk factors are detailed in the Company’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, our prospectus dated March 28, 2005 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.